NCT06413498: An ongoing trial by Kite, A Gilead Company
This trial is ongoing. It must report results 3 years, 11 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06413498 |
|---|---|
| Title | A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 23, 2024 |
| Completion date | July 31, 2028 |
| Required reporting date | July 31, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Aug. 22, 2025 |
| Days late | None |